Listed by the USPTO as DAVIS, RUTH A
Tech Center 1600 • Art Units: 1645 1651 1653 1699
This examiner grants 61% of resolved cases
DAVIS, RUTH A is assigned to Tech Center 1600 and Art Unit 1645. Her record includes 921 resolved cases, with an allowance rate of 61.0%. The median time to allowance is 1168 days, and interview lift is 30.9%, indicating a positive association between interviews and allowance outcomes.
The leading companies are DSM IP Assets B.V., Ipsen Biopharm Limited, and Genmont Biotech Incorporation. The leading firms are Casimir Jones, S.C., NIXON & VANDERHYE, PC, and PROSKAUER ROSE LLP. The profile supports preparing technically focused interview agendas while maintaining detailed written claim analysis. The allowance rate and median timeline suggest that applications may require substantive prosecution over an extended period before resolution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18885857 | MANUFACTURING METHOD OF MIXED POWDER, MIXED POWDER, POWDER, AND POWDER MEDIUM | Non-Final OA | FUJIFILM Corporation |
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18840767 | USES OF BIFIDOBACTERIUM LONGUM MICROORGANISMS HAVING THE CAPACITY TO DEGRADE BOTH HMO AND PLANT-DERIVED GLYCANS | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | Final Rejection | Ipsen Biopharm Limited |
| 17759674 | TREATMENT OF SKIN CONDITIONS | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18872675 | COMBINATIONS COMPRISING VITAMIN C AND LACTOBACILLUS RHAMNOSUS | Non-Final OA | DSM IP Assets B.V. |
| 18834722 | YARROWIA PRODUCTION PROCESS | Non-Final OA | DSM IP ASSETS B.V. |
| 18775012 | ENGINEERED PROBIOTICS FOR DETECTION OF GASTROINTESTINAL DISEASE IN HUMANS | Non-Final OA | Northwestern University |
| 18867205 | MICROORGANISM BELONGING TO GENUS AKKERMANSIA | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18035134 | COMPOSITIONS AND METHODS FOR SCREENING PESTICIDES | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 18563088 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | Non-Final OA | The United States Government, as Represented by the Department of Veterans Affairs |
| 18836135 | USE OF PROBIOTICS FOR MODULATING ALLERGIC IMMUNE RESPONSES | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18541764 | DEVICES AND METHODS FOR DETECTING PANCREATIC LIPASE | Final Rejection | IDEXX LABORATORIES, INC. |
| 18687533 | ENZYME AGENT FOR TRANSESTERIFICATION, INCLUDING LIPASE AS ACTIVE INGREDIENT | Non-Final OA | AMANO ENZYME INC. |
| 18254449 | DESIGNED BACTERIAL COMPOSITIONS FOR TREATING GRAFT-VERSUS-HOST-DISEASE | Non-Final OA | Seres Therapeutics, Inc. |
| 17767725 | METHOD FOR PREVENTING HUMAN GLANDS FROM RADIATION DAMAGE | Final Rejection | MERZ THERAPEUTICS GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy61.0% of resolved applications examined by Ruth A Davis were allowed (921 resolved cases), compared with 49.4% across Art Unit 1645 over the last five years.
This examiner's interview lift is +30.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ruth A Davis took 1,168 days on average from filing to allowance.
Ruth A Davis examines applications in Art Unit 1645 in Tech Center 1600 (Biotechnology & Pharmaceuticals).